207_Combined course Presentations
Toxicity of concurrent SRT and antibody therapy
Anti-Her2 (trastuzumab)
Very limited available data does not indicate increased toxicity of cranial SRT combined with trastuzumab.
Data on trastuzumab and extra-cranial SRT is lacking.
Kroeze S et al. Cancer Treatment Reviews 53 (2017) 25–37
Made with FlippingBook